The serum from a patient with lupus nephritis, insulin resistance, and hypoglycemia was studied. This serum both inhibits the binding of P atients with immunologic diseases, who have antibodies that have the ability to both inhibit the binding of labeled insulin to its receptor and to mimic the actions of insulin on many biologic functions, have been reported. 1 -7 Generally, these patients have the clinical symptoms of hyperglycemia, but occasionally, patients may have hypoglycemia, or a combination of hyperand hypoglycemia. 189 It is not known, however, whether the ability to inhibit the binding of insulin and the ability to mimic insulin action reside in one population of antibodies in several different classes of antibodies that have different effects. In order to investigate these possibilities, we have studied the serum of a patient with lupus nephritis, insulin resistance, hypoinsulinemia, and hypoglycemia.
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P atients with immunologic diseases, who have antibodies that have the ability to both inhibit the binding of labeled insulin to its receptor and to mimic the actions of insulin on many biologic functions, have been reported. 1 -7 Generally, these patients have the clinical symptoms of hyperglycemia, but occasionally, patients may have hypoglycemia, or a combination of hyperand hypoglycemia. 189 It is not known, however, whether the ability to inhibit the binding of insulin and the ability to mimic insulin action reside in one population of antibodies in several different classes of antibodies that have different effects. In order to investigate these possibilities, we have studied the serum of a patient with lupus nephritis, insulin resistance, hypoinsulinemia, and hypoglycemia. 1 This serum both inhibits 125 l-insulin binding to its receptor and stimulates glucose transport and oxidation in isolated rat adipocytes. 2 To test whether multiple populations of antibodies were involved in these activities, the IgG from this serum was fractionated on a protein A-Sepharose affinity column and the separate fractions were then tested for their ability to interact with the insulin receptor and to stimulate glucose transport in isolated rat adipocytes.
MATERIALS AND METHODS
The patient's serum was precipitated in 33% ammonium sulfate, suspended in potassium phosphate 0.01 M (pH 8.0) buffer, and applied to a DEAE cellulose (DE 52, Whatman, Ltd., Kent, UK) column equilibrated in 0.01 M phosphate buffer (pH 8.0). The eluate was concentrated against dry Sephadex G-200 and subsequently dialyzed three times at 4°C against phosphate (pH 7.4) buffer. Thereafter, aliquots used to perform binding or glucose transport studies were dialyzed twice at 4°C for 24 h against the same buffer used in subsequent experiments. An aliquot (-40 mg/ml) of the patient's IgG suspended in Tris 0.05 M, NaCI 0.15 M (pH 9.0) buffer was absorbed at 4°C into a column containing 14 mg protein A (protein A-Sepharose CL 4B, Pharmacia Fine Chemicals, Uppsala, Sweden), gel volume 7 ml, equilibrated in Tris 0.05 M, NaCI 0.15 M (pH 9.0) buffer. The column was then washed with 30 ml Tris buffer and eluted by applying sequentially: (1) l-monoclonal antibody binding to IM-9 human lymphocytes were carried out in buffer containing 100 mM Hepes, 120 mM NaCI, 1.5 mM EDTA, 15 mM Na-acetate, 10 mM glucose (pH 7.8) with bovine serum albumin at 10 mg/ml. One to two x 10 6 cells/ml were incubated with either 125 l-insulin (100 pM; 130 Ci/g) or ^^-monoclonal antibody (60 pM; 10 Ci/g), prepared as previously reported in detail, 10 in the presence or absence of different amounts of insulin, monoclonal antibody, normal human IgG (Sigma Chemicals, St. Louis, Missouri), and unfractionated or fractionated patient's IgG for 70 min at 15°C in a total volume of 0.5 ml. 10 125 l-insulin binding and 2-deoxy-D-glucose uptake in isolated adipocytes were carried out on cells prepared from epididymal fat pads obtained from male Sprague-Dawley rats (140-180 g) according to the method of Rodbell.
11 125 Iinsulin binding studies were carried out by adding 125 l-insulin (100 pM) to 2 x 10 5 cells/ml suspended in 35 mM Tris, 120 mM NaCI, 5 mM MgSo 4 , 10 mM glucose, 2 mM CaCI 2 , 24 mM Na-acetate, and 10 mg/ml bovine serum albumin (pH 7.6), in the presence or absence of insulin, unfractionated or fractionated patient's IgG for 90 min at 24°C. 12 Glucose transport studies were carried out on 2 x 10 5 cells/ml incubated in Krebs-Ringer bicarbonate (pH 7.4) buffer in the presence or absence of insulin, normal human IgG (Sigma Chemicals), and unfractionated or fractionated patient's IgG for 60 min at 24°C; thereafter, each sample was incubated with 2-deoxy- [1- 3 H]-D-glucose (0.4 ^Ci/ml) (New England Nuclear, Boston, Massachusetts) plus 0.1 mM 2-deoxy-Dglucose (Sigma Chemicals) at 24°C for 3 min.
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RESULTS
Unlabeled insulin inhibits the binding of labeled insulin to IM-9 lymphocytes with one-half maximal activity occurring at 200 pM, mouse monoclonal antireceptor antibody with one-half maximal activity occurring at 4 nM, and the unfractionated IgG with one-half maximal activity occurring at 1 ixM. In contrast, normal human IgG was without effect on 125 l-insulin binding ( Figure 1A) . Next, unlabeled insulin competed with the binding of labeled monoclonal antibody with one-half maximal activity occurring at 400 pM, and with the binding of unlabeled monoclonal antibody with one-half maximal activity occurring at 2 nM. Unfractionated IgG, in contrast, was a very weak inhibitor of labeled monoclonal antibody binding since at a concentration of 4 |xM only 35% of the labeled monoclonal antibody was inhibited ( Figure 1B) ; moreover, at this concentration, normal human IgG interfered with labeled monoclonal antibody binding ( Figure 1B) .
The four antibody fractions isolated from the protein A column were then studied for their ability to inhibit the binding of labeled insulin to IM-9 lymphocytes. Antibodies eluted at pH 3.3 inhibited binding approximately one-half as well as the unfractionated IgG; the fractions at pH 5.5 and 2.3 had even less potency, and the fraction eluted at pH 4.3 was without activity (Figure 2A) . Next, the effect of these fractions were studied on labeled monoclonal antibody binding to the insulin receptor ( Figure 2B) . The fraction at pH 3.3 one-half maximally inhibited labeled antibody binding at concentrations tenfold lower than those of the unfractionated IgG. In contrast, the other fractions had negligible effects on labeled monoclonal antibody binding, and were not different from normal IgG ( Figure 2B ). The effect of fractionated IgG on labeled insulin binding to isolated adipocytes was comparable with that obtained in experiments carried out on IM-9 cells. In fact, the pH 4.3 fraction was unable to inhibit insulin binding to adipocytes, whereas three fractions (pH 5.5, 3.3, and 2.3) inhibited the binding of insulin to its receptor; however, no fraction was more potent than unfractionated IgG by itself (data not shown).
We have previously reported that the serum from this patient stimulated glucose transport and other activities in isolated rat adipocytes. 2 In the present study, the unfractionated IgG from this serum was active in stimulating deoxyglucose transport with one-half maximal effect occurring at 5 jxM (Figure 3) . When the IgG fractions were studied the fraction at pH 5.5 was more potent than unfractionated IgG, with one-half maximal effect occurring at 400 nM. The fraction at pH 3.3, which had the greatest receptor binding activity, had an activity on transport that was slightly less than that for the unfractionated IgG. The remaining two fractions, as well as normal human IgG, were without effect (Figure 3) .
DISCUSSION
In the present study, we have analyzed the serum from a female patient with hypoglycemia provoked by anti-insulin receptor antibodies and lupus nephritis as diagnosed by renal biopsy. 1 Studies with cells in vitro have indicated that the antireceptor sera from patients with both hyper-and hypoglycemia inhibit the binding of labeled insulin to its receptor in several cell types, and, in addition, mimic many of the actions of insulin.
37 It has been observed, however, that sera from some patients have a marked ability to inhibit insulin binding and a relatively weaker ability to stimulate biologic functions. 13 Conversely, other sera have a relatively weak potency to inhibit insulin binding and a relatively stronger potency to stimulate biologic activity. 13 On the basis of these data, it has been hypothesized that these antireceptor sera contain different populations of antireceptor antibodies. 13 In order to understand the ability of these sera to inhibit the binding of insulin to its receptor and to mimic insulin action, we previously prepared from mice a monoclonal antibody to the human insulin receptor. This monoclonal antibody competes with insulin for the binding to its receptor to human but not animal cells, 1014 it does not mimic the actions of insulin, 10 and when added with insulin it blocks insulin's effects. 10 To study the nature of the antibodies present in this patient's serum, we first investigated the ability of the patient's IgG to inhibit the binding of both labeled insulin and labeled monoclonal antibody to the insulin receptor. The IgG from the patient's serum inhibited the binding of insulin to its receptor but showed relatively lower potency in inhibiting the binding of labeled monoclonal antibody to the insulin receptor. Next, we fractionated the patient's IgG by affinity chromatography over protein A-Sepharose. Four protein peaks were obtained with this procedure. Three of the fractions (pH 5.5, 3.3, and 2.3) inhibited the binding of insulin to its receptor, but no fraction was more potent than unfractionated IgG by itself. In contrast, however, one fraction (pH 3.3) was able to inhibit the binding of the monoclonal antibody to its receptor and this fraction was more potent than unfractionated IgG. These studies suggested, therefore, that (1) the patient's serum contains several IgG populations that displayed varying abilities to inhibit the binding of insulin to its receptor; (2) the insulin binding site is a complex molecule with several antigenic sites since the monoclonal antibody and major part of the patient's antibodies were directed toward different determinants.
When deoxyglucose transport was studied, only two fractions (pH 5.3 and 3.3) mimicked the stimulation of insulin. Of interest was that the fraction eluted at pH 5.5 had a relatively weak ability to inhibit insulin binding but had a marked ability to stimulate transport. These data further indicate that the serum from this patient contains multiple populations of antibodies. Moreover, comparison of data obtained with IgG eluted at pH 5.5 and 3.3 indicates that certain antibodies have major effects on insulin binding, whereas other antibodies have major effects to mimic insulin action.
The present studies suggest, therefore, that there are different populations of antibodies that recognize different antigenic sites. Thus, there are antibodies whose predominant activity is to inhibit insulin binding and antibodies whose predominant activity is to mimic insulin action. The latter may not even be directed against the insulin receptor since it has been shown that antibodies directed toward various membrane proteins of adipocytes mimic the effects of insulin.
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These findings may explain, therefore, the clinical symptoms of either hyper-or hypoglycemia seen in patients since the clinical course may depend on the relative concentrations of these different types of antibodies. zione and Universita di Roma "La Sapienza" Progetto "Funzioni di Membrana."
